Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide

LAUR Repository

Show simple item record

dc.contributor.author Milane, Aline
dc.contributor.author Goldwirt, Lauriane
dc.contributor.author Beccaria, Kevin
dc.contributor.author Carpentier, Alexandre
dc.contributor.author Idbaih, Ahmed
dc.contributor.author Schmitt, Charlotte
dc.contributor.author LEvasseur, Camille
dc.contributor.author Labussiere, Marianne
dc.contributor.author Farinotti, Robert
dc.contributor.author Fernandez, Christine
dc.date.accessioned 2016-10-05T06:16:18Z
dc.date.available 2016-10-05T06:16:18Z
dc.date.copyright 2015 en_US
dc.date.issued 2016-10-05
dc.identifier.issn 0167-594X en_US
dc.identifier.uri http://hdl.handle.net/10725/4503
dc.description.abstract Glioblastoma (GBM) is the most common primary malignant brain tumour in adults. Prognosis of GBM patients is poor with median overall survival around 15 months. Temozolomide is the chemotherapeutic agent used in the standard of care of newly diagnosed GBM patients relying on radiotherapy with concurrent chemotherapy followed by chemotherapy alone. Irinotecan has shown some efficacy in recurrent malignant gliomas. Bevacizumab has been combined with irinotecan in the treatment of recurrent GBM and with temozolomide in newly diagnosed GBM. As the efficacy of GBM treatments relies on their brain distribution through the blood brain barrier, the aim of the present preclinical work was to study, in in vivo models, the impact of bevacizumab on brain and tumor distribution of temozolomide and irinotecan. Our results show that bevacizumab pre-treatment was associated with a reduced temozolomide brain distribution in tumor-free mice. In tumor bearing mice, bevacizumab increased temozolomide tumor distribution, although not statistically significant. In both tumor-free and tumor-bearing mice, bevacizumab does not modify brain distribution of irinotecan and its metabolite SN-38. Bevacizumab impacts brain distribution of some anti-tumor drugs and potentially their efficacy in GBM. Further studies are warranted to investigate other therapeutic combination. en_US
dc.language.iso en en_US
dc.title Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOP en_US
dc.author.idnumber 200904164 en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Journal of Neuro-Oncology en_US
dc.journal.volume 122 en_US
dc.journal.issue 2 en_US
dc.article.pages 273-281 en_US
dc.keywords Irinotecan en_US
dc.keywords SN-38 en_US
dc.keywords Temozolomide en_US
dc.keywords Tumor distribution en_US
dc.keywords Brain distribution en_US
dc.keywords Glioblastoma en_US
dc.identifier.doi http://dx.doi.org10.1007/s11060-015-1717-1 en_US
dc.identifier.ctation Goldwirt, L., Beccaria, K., Carpentier, A., Idbaih, A., Schmitt, C., Levasseur, C., ... & Fernandez, C. (2015). Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide. Journal of neuro-oncology, 122(2), 273-281. en_US
dc.author.email aline.milane@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url http://link.springer.com/article/10.1007/s11060-015-1717-1 en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account